Elmind Capital LP bought a new stake in Septerna, Inc. (NASDAQ:SEPN – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 49,444 shares of the company’s stock, valued at approximately $1,655,880,000.
Several other institutional investors have also recently bought and sold shares of the company. Deutsche Bank AG boosted its position in Septerna by 5.3% during the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after acquiring an additional 744 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of Septerna in the fourth quarter worth $35,000. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares during the last quarter. PharVision Advisers LLC grew its position in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares in the last quarter. Finally, Nuveen LLC grew its position in Septerna by 7.7% in the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock valued at $719,000 after purchasing an additional 1,837 shares in the last quarter.
Septerna Price Performance
Septerna stock opened at $41.30 on Wednesday. The company’s 50-day moving average is $37.06 and its 200-day moving average is $30.54. The firm has a market capitalization of $1.93 billion, a PE ratio of -76.48 and a beta of 2.29. Septerna, Inc. has a fifty-two week low of $11.70 and a fifty-two week high of $51.10.
Analysts Set New Price Targets
Several brokerages have commented on SEPN. Guggenheim boosted their price target on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. increased their price target on Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research report on Wednesday, August 19th. HC Wainwright raised their price target on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Truist Financial boosted their price target on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Finally, JonesTrading upped their price objective on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $52.44.
Get Our Latest Stock Report on SEPN
Insider Activity
In related news, insider Samira Shaikhly sold 2,178 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider owned 793 shares in the company, valued at approximately $27,897.74. This represents a 73.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $7,665,196. This represents a 12.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 61,030 shares of company stock valued at $2,329,666 over the last three months. Insiders own 5.80% of the company’s stock.
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Featured Articles
- Five stocks we like better than Septerna
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding SEPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Septerna, Inc. (NASDAQ:SEPN – Free Report).
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
